PFA Has Been a Game-Changer for Heart Patients—But There Are Still Risks

Why It Matters

The technology promises faster, safer AFib ablations, but emerging safety signals could shape procedural protocols and influence device design choices across the electrophysiology market.

Key Takeaways

• PFA offers non‑thermal ablation with reduced phrenic nerve injury
• Coronary artery spasm, including generalized spasm, reported in <1% cases
• Hemolysis risk linked to catheter designs that expose blood to energy
• Registries like MANIFEST‑US and TRACE‑AF track post‑PFA safety data
• Larger‑footprint catheters improve tissue contact, reducing hemolysis

Pulse Analysis

Pulsed field ablation has quickly moved from experimental labs to the front‑line of atrial fibrillation therapy, driven by its non‑thermal mechanism that spares surrounding structures. The market now hosts a suite of catheters—Medtronic’s PulseSelect, Boston Scientific’s Farapulse, Johnson & Johnson’s VariPulse, Kardium’s Globe, and Abbott’s Volt balloon—each promising easier navigation and larger tissue contact. This device diversity fuels competition, shortens procedure times, and positions PFA as a potential new standard of care for electrophysiologists seeking to reduce complications associated with traditional thermal ablation.

Despite the safety hype, clinicians are encountering rare but serious events that could temper enthusiasm. Coronary artery spasm, both proximity‑related and generalized, has been observed in under 1% of cases, occasionally triggering ventricular arrhythmias or sudden death. Hemolysis, another emerging issue, correlates with catheter designs that allow electrodes to float in blood, releasing pulsed energy into the circulation. Operators are responding with prophylactic nitroglycerin, pre‑hydration, and stricter reliance on intracardiac echocardiography to confirm tissue contact, while manufacturers refine electrode geometry to focus energy delivery.

The broader implication for the cardiac device industry is clear: safety data will drive the next wave of innovation and regulatory scrutiny. Registries such as MANIFEST‑US and the upcoming TRACE‑AF provide a real‑world evidence base that can inform best‑practice guidelines and shape reimbursement models. As the evidence pool matures, hospitals and EP labs will likely adopt risk‑mitigation protocols, and manufacturers that demonstrate lower spasm and hemolysis rates could capture a decisive market advantage, ultimately improving outcomes for millions of AFib patients.